Allergan plc and Molecular Partners a clinical-stage biopharmaceutical company developing a new class of drugs known as DARPin therapies, announced...
Allergan plc,and Molecular Partners a clinical-stage biopharmaceutical company developing a new class of drugs known as DARPin therapies, announced two-year...
LivaNova PLC announced the the first successful implantation of the Vitaria System in a patient enrolled in the Autonomic Regulation...
Background:Although factor Xa inhibitors have become a popular choice for chronic oral anticoagulation, effective drug reversal remains difficult due to a lack of specific antidote.